Targeted gene deletion of prolyl hydroxylase domain protein 3 triggers angiogenesis and preserves cardiac function by stabilizing hypoxia inducible factor 1 alpha following myocardial infarction

Current Pharmaceutical Design

Volumn 20, Issue 9, 2014, Pages 1305-1310

  Oriowo, Babatunde ^a   Thirunavukkarasu, Mahesh ^a   Selvaraju, Vaithinathan ^a   Adluri, Ram Sudheer ^a   Zhan, Lijun ^a   Takeda, Kotaro ^a   Fong, Guo Hua ^a   Sanchez, Juan A ^a   Maulik, Nilanjana ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Angiogenesis; Bcl 2; HIF; Myocardial infarction; Prolyl hydroxylase; VEGF

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROLYL HYDROXYLASE DOMAIN 1; PROLYL HYDROXYLASE DOMAIN 2; PROLYL HYDROXYLASE DOMAIN 3; UNCLASSIFIED DRUG; PHD1 PROTEIN, MOUSE; PHD3 PROTEIN, MOUSE;

ADULT; ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CAPILLARY DENSITY; CONTROLLED STUDY; ELECTROPHORESIS; GENE DELETION; GENE INACTIVATION; HEART EJECTION FRACTION; HEART FUNCTION; HEART INFARCTION; HUMAN; HUMAN CELL; LEFT CORONARY ARTERY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; ANIMAL; DISEASE MODEL; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOPHYSIOLOGY; REPERFUSION INJURY; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE DELETION; GENE EXPRESSION REGULATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, KNOCKOUT; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; NEOVASCULARIZATION, PHYSIOLOGIC; PROCOLLAGEN-PROLINE DIOXYGENASE;

EID: 84896350565     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990549     Document Type: Article

References (32)

1. Wang Y, Gabrielsen A, Lawler PR, et al. Myocardial gene expression of angiogenic factors in human chronic ischemic myocardium: influence of acute ischemia/cardioplegia and reperfusion. Microcirculation 2006; 13: 187-97.
2. Berra E, Ginouves A, Pouyssegur J. The hypoxia-inducible-factor hydroxylases bring fresh air into hypoxia signalling. EMBO Rep 2006; 7: 41-5.
3. Cummins EP, Berra E, Comerford KM, et al. Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc Natl Acad Sci U S A 2006; 103: 18154-9.
4. Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 2002; 295: 858-61.
5. Schofield CJ, Ratcliffe PJ. Signalling hypoxia by HIF hydroxylases. Biochem Biophys Res Commun 2005; 338: 617-26.
6. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, Pouyssegur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 2003; 22: 4082-90.
7. Aminova LR, Chavez JC, Lee J, et al. Prosurvival and prodeath effects of hypoxia-inducible factor-1alpha stabilization in a murine hippocampal cell line. J Biol Chem 2005; 280: 3996-4003.
8. Sen Banerjee S, Thirunavukkarasu M, Rishi MT, Sanchez JA, Maulik N, Maulik G. HIF-prolyl hydroxylases and cardiovascular diseases. Toxicol Mech Methods 2012; 22: 347-58.
9. Adluri RS, Thirunavukkarasu M, Dunna NR, et al. Disruption of hypoxia-inducible transcription factor-prolyl hydroxylase domain-1 (PHD-1-/-) attenuates ex vivo myocardial ischemia/reperfusion injury through hypoxia-inducible factor-1alpha transcription factor and its target genes in mice. Antioxid Redox Signal 2011; 15: 1789-97.
10. Bao W, Qin P, Needle S, et al. Chronic inhibition of hypoxiainducible factor prolyl 4-hydroxylase improves ventricular performance, remodeling, and vascularity after myocardial infarction in the rat. J Cardiovasc Pharmacol 2010; 56: 147-55.
11. Natarajan R, Salloum FN, Fisher BJ, Smithson L, Almenara J, Fowler AA, 3rd. Prolyl hydroxylase inhibition attenuates postischemic cardiac injury via induction of endoplasmic reticulum stress genes. Vascul Pharmacol 2009; 51: 110-8.
12. Ockaili R, Natarajan R, Salloum F, et al. HIF-1 activation attenuates postischemic myocardial injury: role for heme oxygenase-1 in modulating microvascular chemokine generation. Am J Physiol Heart Circ Physiol 2005; 289: H542-8.
13. Poynter JA, Manukyan MC, Wang Y, et al. Systemic pretreatment with dimethyloxalylglycine increases myocardial HIF-1alpha and VEGF production and improves functional recovery after acute ischemia/reperfusion. Surgery 2011; 150: 278-83.
14. Rantanen K, Pursiheimo J, Hogel H, Himanen V, Metzen E, Jaakkola PM. Prolyl hydroxylase PHD3 activates oxygendependent protein aggregation. Mol Biol Cell 2008; 19: 2231-40.
15. Bishop T, Gallagher D, Pascual A, et al. Abnormal sympathoadrenal development and systemic hypotension in PHD3-/-mice. Mol Cell Biol 2008; 28: 3386-400.
16. Lipscomb EA, Sarmiere PD, Freeman RS. SM-20 is a novel mitochondrial protein that causes caspase-dependent cell death in nerve growth factor-dependent neurons. J Biol Chem 2001; 276: 5085-92.
17. Koditz J, Nesper J, Wottawa M, et al. Oxygen-dependent ATF-4 stability is mediated by the PHD3 oxygen sensor. Blood 2007; 110: 3610-7.
18. Takeda K, Ho VC, Takeda H, Duan LJ, Nagy A, Fong GH. Placental but not heart defects are associated with elevated hypoxia-inducible factor alpha levels in mice lacking prolyl hydroxylase domain protein 2. Mol Cell Biol 2006; 26: 8336-46.
19. Adluri RS, Thirunavukkarasu M, Zhan L, et al. Thioredoxin 1 enhances neovascularization and reduces ventricular remodeling during chronic myocardial infarction: a study using thioredoxin 1 transgenic mice. J Mol Cell Cardiol 2011; 50: 239-47.
20. Junqueira LC, Bignolas G, Brentani RR. Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem J 1979; 11: 447-55.
21. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389-95.
22. Harris AL. Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47.
23. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003; 9: 677-84.
24. Appelhoff RJ, Tian YM, Raval RR, et al. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 2004; 279: 38458-65.
25. Warnecke C, Griethe W, Weidemann A, et al. Activation of the hypoxia-inducible factor-pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors. FASEB J 2003; 17: 1186-8.
26. Aragones J, Schneider M, Van Geyte K, et al. Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet 2008; 40: 170-80.
27. Eckle T, Kohler D, Lehmann R, El Kasmi K, Eltzschig HK. Hypoxia-inducible factor-1 is central to cardioprotection: a new paradigm for ischemic preconditioning. Circulation 2008; 118: 166-75.
28. Kelly DP. Hypoxic reprogramming. Nat Genet 2008; 40: 132-4.
29. Ramirez JM, Folkow LP, Blix AS. Hypoxia tolerance in mammals and birds: from the wilderness to the clinic. Annu Rev Physiol 2007; 69: 113-43.
30. Schmitz A, Harrison JF. Hypoxic tolerance in air-breathing invertebrates. Respir Physiol Neurobiol 2004; 141: 229-42.
31. Samuel SM, Akita Y, Paul D, et al. Coadministration of adenoviral vascular endothelial growth factor and angiopoietin-1 enhances vascularization and reduces ventricular remodeling in the infarcted myocardium of type 1 diabetic rats. Diabetes 2010; 59: 51-60.
32. Liu Y, Huo Z, Yan B, et al. Prolyl hydroxylase 3 interacts with Bcl-2 to regulate doxorubicin-induced apoptosis in H9c2 cells. Biochem Biophys Res Commun 2010; 401: 231-7.